中国麻风皮肤病杂志 ›› 2026, Vol. 42 ›› Issue (6): 470-474.doi: 10.12144/zgmfskin202606470

• 综述 • 上一篇    

氘可来昔替尼在免疫介导性皮肤病中的应用进展

李瑞1,钏锦涛2,张佩莲1   

  1. 1云南省中医医院，云南昆明，650021；2云南中医药大学第一临床医学院，云南昆明，650021
  • 出版日期:2026-06-15 发布日期:2026-06-04

Advance of deucravacitinib in the treatment of immune-mediated dermatoses

LI Rui1, CHUAN Jintao2, ZHANG Peilian1   

  1. 1 Yunnan Provincial Hospital of Traditional Chinese Medicine, Kunming 650021, China; 2 The First Affiliated Hospital of Yunnan University of Traditional Chinese Medicine, Kunming 650021, China
  • Online:2026-06-15 Published:2026-06-04

PDF (PC)

6

摘要： 氘可来昔替尼（deucravacitinib，DEUC)是一种高选择性变构型酪氨酸激酶2（tyrosine kinase 2,TYK2）抑制剂，是Janus激酶家族成员，特异性介导IL-12、IL-23及I-IFN等细胞因子的细胞内信号转导，已获批治疗中重度斑块型银屑病、活动性银屑病关节炎。近年来，DEUC已超适应症应用于对传统系统治疗疗效欠佳的免疫介导性皮肤病及风湿性疾病，包括系统性红斑狼疮、扁平苔藓、斑秃及系统性硬化症等。本文系统总结现有临床证据，探讨DEUC在上述疾病中的疗效、安全性及作用机制，为临床靶向治疗提供参考。

关键词: 氘可来昔替尼, TYK2抑制剂, 银屑病, 银屑病关节炎, 系统性红斑狼疮, 扁平苔藓, 斑秃, 系统性硬化症

Abstract: Deucravacitinib (DEUC) is a highly selective allosteric tyrosine kinase 2 (TYK2) inhibitor, a member of the Janus kinase family. It specifically mediates the intracellular signal transduction of cytokines such as IL-12, IL-23, and type I interferons (IFN-I), and has been approved for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis. In recent years, DEUC has been used off-label for immune-mediated dermatological disorders and rheumatic diseases with inadequate response to conventional systemic therapies, including systemic lupus erythematosus, lichen planus, alopecia areata, and systemic sclerosis. This article systematically summarizes the available clinical evidence, discusses the efficacy, safety, and mechanism of action of DEUC in the above diseases, and provides a reference for clinical targeted therapy.

Key words: deucravacitinib, TYK2 inhibitor, psoriasis, psoriatic arthritis, systemic lupus erythematosus, lichen planus, alopecia areata, systemic sclerosis